undamentalytics Newsletter
Sign in

Cue Biopharma, Inc. income statement

In fiscal 2025, Cue Biopharma, Inc. reported revenue of $27.5m, up 195.7% on the year before, operating income of −$26.6m (a -96.7% margin) and net income of −$26.6m, or −$0.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue133151592738
Research and development292734413941363877
General and administrative111315171617151659
Operating income−39−37−45−44−53−52−42−27−99
Interest expense————0000—
Net interest income———0−1−1−1−0−0
Income before tax−38−36−45−44−53————
Income tax10000—01—
Net income−39−37−45−44−53−51−41−27−164
Diluted EPS−$1.94−$1.66−$1.56−$1.41−$1.49−$1.11−$0.72−$0.28—
Diluted shares (average)20m22m29m31m36m46m56m95m—
EBITDA−38−36−44−42−52−52−41−26−97

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CUE vs ZYMECUE vs NBTXCUE vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cue Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cue Biopharma, Inc.